Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.
Category: News
Celebrating 30 Million Optomap® Patients Around The World
LONDON, UK, 29 June 2011 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announced that it reached an important milestone for its ultra-widefield retinal imaging product line – capturing images for 30 million optomap patients.
Scil Proteins Signs Licensing And Pre Manufacturing Agreement With Anabasis/Dompé For Eye Indications
Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.
Wary of Employment But Still Tempted?
There are ways to get some of the benefits of hospital employment without fully giving up your practice or autonomy. Find out what they are. Medscape Business of Medicine
The Sustainable Growth Rate — What Happens Now?
Senator Tom Coburn describes the future of Medicare reimbursements and comments on other issues of concern for physicians, such as tort reform and the individual mandate in the Affordable Care Act. Medscape Internal Medicine
Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases
Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.
Latanoprost Effective, Safe as Timolol for Glaucoma in Kids
In a head-to-head trial, latanoprost was noninferior to timolol for treating glaucoma in children, according to a report in Ophthalmology online June 16. Reuters Health Information
Mediphacos To Launch The MFR2, A New Generation Of Acrylic IOLs at The 29th Pan-American Congress Of Ophthalmology (PAAO) 7-9 July 2011, Buenos Aires, Argentina
On behalf of Mediphacos Ltda. (Belo Horizonte, Brazil), we would like to invite you to learn about Mediphacos’ new generation of acrylic IOLs, the MFR2, at the upcoming Pan-American Congress of Ophthalmology meeting in Buenos Aires, Argentina (7-9 July…
TZD Use May Increase Risk for Diabetic Macular Edema
A British study of more than 100,000 patients suggests a link between thiazolidinedione (TZD) use and an increased incidence of diabetes-related macular edema. Medscape Medical News
Eye Implant OZURDEX(R) Receives European Medicines Agency Authorisation For Non-Infectious Uveitis
Allergan announced today that the European Medicines Agency (EMA) has extended the Marketing Authorisation for OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) in the 27 member states of the European Union to include the treatment of …
Leave Fireworks To The Professionals This Fourth Of July: American Academy Of Ophthalmology Offers Tips For Fireworks Safety
Each Fourth of July, thousands of people are injured from using consumer fireworks. According to the U.S. Consumer Product Safety Commission, more than 9,000 fireworks-related injuries happen each year. Of these, nearly half are head-related injuries w…
Positive results from RISE and RIDE Phase III trials of Genentech’s Lucentis for diabetic macular edema
Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).
Neuroscientists Find Famous Optical Illusion Surprisingly Potent
Scientists have come up with new insight into the brain processes that cause the following optical illusion: The yellow jacket (Rocky, the mascot of the University of Rochester) appears to be expanding. But he is not. He is staying still. We simply…
LCA-Vision Announces Management Resignation
LCA-Vision Inc. , a leading provider of laser vision correction services under the LasikPlus® brand, today announced that Marcello J. Celentano has resigned as Senior Vice President of Operations effective July 11, 2011 to lead a company outside of th…
A Comparison of Ophthalmic Electronic Medical Record Systems
Technology Spotlight
Leave Fireworks To The Professionals This Fourth Of July: American Academy Of Ophthalmology Offers Tips For Fireworks Safety
Each Fourth of July, thousands of people are injured from using consumer fireworks. According to the U.S. Consumer Product Safety Commission, more than 9,000 fireworks-related injuries happen each year. Of these, nearly half are head-related injuries w…
Leave Fireworks To The Professionals This Fourth Of July: American Academy Of Ophthalmology Offers Tips For Fireworks Safety
Each Fourth of July, thousands of people are injured from using consumer fireworks. According to the U.S. Consumer Product Safety Commission, more than 9,000 fireworks-related injuries happen each year. Of these, nearly half are head-related injuries w…
Leave Fireworks To The Professionals This Fourth Of July: American Academy Of Ophthalmology Offers Tips For Fireworks Safety
Each Fourth of July, thousands of people are injured from using consumer fireworks. According to the U.S. Consumer Product Safety Commission, more than 9,000 fireworks-related injuries happen each year. Of these, nearly half are head-related injuries w…
ADA: Anti-VEGF ‘Impressive’ In Sharpening Vision
The good news continues to roll in for ranibizumab (Lucentis) in diabetic macular edema with positive results from the RIDE and RISE trials.
Mimetogen Pharmaceuticals Inc. Announces Positive Top Line Data From Phase II Clinical Trial Of MIM-D3 For Dry Eye Disease
Mimetogen Pharmaceuticals Inc. (“Mimetogen”) today announced positive top line data from a Phase II clinical trial with MIM-D3, its lead drug for the treatment of dry eye. The trial demonstrated statistically significant improvements in signs and sympt…